Irinotecano Accord (Irinotecan Hydrochloride Trihydrate)

Irinotecan is converted inside cells to the active metabolite SN‑38, which inhibits topoisomerase I. This enzyme normally relieves DNA supercoiling during replication; its inhibition causes DNA strand breaks, halting replication and triggering apoptosis of rapidly dividing cancer cells.

The specific dose and schedule of Irinotecano Accord are determined by the prescribing oncologist based on factors such as disease stage, patient weight, liver function, and prior therapies. Only a qualified healthcare professional should set the dosing regimen.

Irinotecan is classified as contraindicated in pregnancy unless the potential benefit outweighs the risk to the fetus. It is also not recommended during breastfeeding because it can be excreted in milk and may harm the infant. Consultation with a specialist is essential.

To place an order, submit an enquiry on the Irinotecano Accord product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Irinotecan belongs to the topoisomerase I inhibitor class, offering a distinct mechanism from fluoropyrimidines or oxaliplatin. It is often combined with these agents to enhance efficacy. Compared with other options, irinotecan provides a valuable alternative for patients who have progressed on or are unsuitable for other regimens.

Irinotecano Accord should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and sterility.

The medication is given as an intravenous infusion, typically over 30 to 90 minutes depending on the protocol. Administration is performed by qualified healthcare personnel in a clinical setting, with monitoring for infusion‑related reactions and vital signs.

The most critical risks include severe neutropenia with fever (febrile neutropenia), life‑threatening diarrhea or colitis, cholinergic syndrome, and rare hypersensitivity reactions. Prompt medical attention is required if any of these symptoms develop during or after treatment.

Patients with known hypersensitivity to irinotecan or its excipients, those with uncontrolled infections, severe hepatic impairment, or who are pregnant without a clear therapeutic justification should not receive Irinotecano Accord. A thorough clinical assessment is necessary before initiating therapy.